Member Info for CHELSEA7

A very good post GF, offering a possibility i have given thought too. The point is as you say "we just dont know", the possibilities on the other hand have never been higher. Enjoying this daily rise on very small volumes very much, level 2 has a good look about it, sells are not as easy to come by, and dependant on news another chance to tackle 20 is very possible. We have our ducks lined up in a very clear line, our intentions are pretty clear, and from fleeting moments am happy with the BOD structure, supporting a very fine CSO... We certainly are due news by end of Q2 2018, really not sure how we will get the SCIB1 Combo Trial running by year end, but more than happy to ride dis train. GL everyone.

Buys 160k Sells 23k

10k......................................moving nicely!!

34,000

Panmure have just moved to join two other MMs on 14.5.................................13.5/14.5

Could be more than just that. The BOD are still stating the SCIB1 Combo Trial will start by end of this year.

06/06/2018 09:48 5,000 13.72 06/06/2018 09:05 25,000 13.98 13.5/14.2P

Wild, wasn"t this the trial of one single patient?

Many thanks.

Just about four full months now to we hear the Results of Grand Challenge, just a reminder to it"s importance, particularly in respect of future funding.............................. The world's brightest minds In 2017 with the generous support of our donors and The Dutch Cancer Society (link is external) four remarkable Grand Challenge teams were funded � each receiving up to �20m over the next five years to take on some of the toughest challenges in cancer research.

https://endpts.com/nektar-wants-everyone-to-stay-calm-as-they-carry-on-with-nktr-214-hoping-to-avoid-an-asco-stampede/?utm_medium=email&utm_campaign=493%20Tuesday%206518%20Worthless%20AbbVies%20Rova-T%20gets%20scathing%20assessment%20Tricida%20unloads%20strong%20data%20hours%20after%20IPO%20news&utm_content=493%20Tuesday%206518%20Worthless%20AbbVies%20Rova-T%20gets%20scathing%20assessment%20Tricida%20unloads%20strong%20data%20hours%20after%20IPO%20news+CID_fb3767bc41b7e4510e219ed1513b1a8d&utm_source=ENDPOINTS%20emails&utm_term=Nektar%20wants%20everyone%20to%20stay%20calm%20as%20they%20carry%20on%20with%20NKTR-214%20but%20ASCO18%20spurs%20a%20stampede

A couple of interesting articles from this years Asco. of relevance to SCIB 1/2 too........................... https://am.asco.org/frontline-pembrolizumab-and-chemotherapy-new-standard-care-metastatic-squamous-nsclc https://endpts.com/asco18-abbvie-convinces-one-top-analyst-that-its-6b-megablockbuster-rova-t-is-worthless/?utm_medium=email&utm_campaign=493%20Tuesday%206518%20Worthless%20AbbVies%20Rova-T%20gets%20scathing%20assessment%20Tricida%20unloads%20strong%20data%20hours%20after%20IPO%20news&utm_content=493%20Tuesday%206518%20Worthless%20AbbVies%20Rova-T%20gets%20scathing%20assessment%20Tricida%20unloads%20strong%20data%20hours%20after%20IPO%20news+CID_fb3767bc41b7e4510e219ed1513b1a8d&utm_source=ENDPOINTS%20emails&utm_term=ASCO18%20AbbVie%20convinces%20one%20top%20analyst%20that%20its%206B%20megablockbuster%20Rova-T%20is%20worthless Seems a far more muted Asco this year in terms of exciting new works, but some interesting data and rationale behind th excitement of previous meetings.

Buys 155k Sells 60k

Paid

You guys, talk about patience eh. ATB

So you are still around.Needless to say even having thanked so many decent people for their incredible support tthe trolling goes on. As you well know, or others closer do, cancer, and this sounds weird, was only a small part of my problems. I was so thrilled to have beaten it off for now, however, it still leaves me with 32 known conditions which are deteriative, leaves me on the terminal list and i still have a very short prognosis. So essentially the fact i am clear, at least until September, has made no difference to me at all. For your concern and i truly hope will be the last words on the subject, i rely largely on a wheelchair to go out, able to walk around in my home. Fortunately, i do many things, and if you could get the sun to come out i would gladly sit in the garden all day. If it is OK with you, I choose amongst many other things to share level 2 with whoever appreciates it. If you don"t then please turn the volume down as many people who do not have it or who are in transit do appreciate it. That my friend is hopefully the last, my 20th request on the matter. It is your post, the vile abuse i receive on other BBs, and the bullying and lies that eminate from ADVFN that i endure. Will i ever be able to rid the fact my life was turned upside down five years ago?? Well i rather doubt it, my interest in Oncology has only increased during that time. Unfortunately amongst so much kindness shown to me i have to go through posts like yours. Do i have to explain further??

Open offer raises an extra �1.2m SCLP is a clinical-stage biotechnology company developing two distinct flexible cancer immunotherapy platforms, each with broad applications: ImmunoBody� is a DNA vaccine that stimulates high-avidity anti-tumour CD8 T-cells for use as a monotherapy or in combination with checkpoint inhibitors (CPIs); Moditope� targets modified antigens and stimulates powerful anti-tumour CD4 T-cell responses for use in advanced and hard-to-treat cancers. The company has announced a capital increase by way of a Placing, Subscription and Open offer to raise up to a maximum of �9.5m gross new funds to support and progress its clinical trial programmes. ► Strategy: SCLP is developing two proprietary immuno-oncology platforms that target cancer cells directly to produce potent T-cell responses. Both technologies are highly flexible, potentially targeting many types of cancer. The initial aim is to complete proof-of-concept trials in multiple indications. ► Capital increase: SCLP completed a Placing and Subscription of 62.41m new Ordinary shares at 12p to raise gross new funds of �7.5m (est. �6.9m net in April 2018). In addition, there is a 1-for-19 Open offer at 12p per share to existing shareholders, which has had a good uptake and raised a further �1.2m (gross). ► Use of proceeds: The principal use of funds will be to progress the clinical programmes for both its vaccine technologies. Among others, SCLP will start a late-stage melanoma combination study with SCIB1 + checkpoint inhibitor in 4Q�18, and commence a first-in-man breast clinical trial with Modi-1 in 1H�19. ► Moditope patent: SCLP has been granted a patent from the European Patent Office for its Moditope immunotherapy platform, effective from 13 June 2018. This endorses Moditope as a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications ► Investment summary: SCLP is trading on an EV of ca.�33m, compared with a cumulative investment of �36m to get the company to where it is today, which is low compared with its relevant peers. SCLP�s proprietary technologies are in the �hot� area of immuno-oncology and targeting markets of significant unmet medical need. Recent deals have demonstrated the price that big pharma is willing to pay for validated assets in the field. Financial summary and valuation Open offer raises an extra �1.2m SCLP is a clinical-stage biotechnology company developing two distinct flexible cancer immunotherapy platforms, each with broad applications: ImmunoBody� is a DNA vaccine that stimulates high-avidity anti-tumour CD8 T-cells for use as a monotherapy or in combination with checkpoint inhibitors (CPIs); Moditope� targets modified antigens and stimulates powerful anti-tumour CD4 T-cell

13.20/14

Buys 110k Sells 55k Same patterns buys outweighing sells by 2 to 1 on average. We have seen some decent buying up to 14p last few days. A far cry from the 20/30k daily volumes too.

At 13.522 showing as buys. Most recent trades on NEX are Buys........................... 05/06/2018 11:39 3,940 13.73 05/06/2018 11:10 4,005 13.73